RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Quintiles, a leading global biopharmaceutical services company, today announced the release of Quintiles Infosario, a business-to-business platform that enables customers to leverage data for improved collaboration and decision-making throughout the drug development process.
“Quintiles Infosario is a fully integrated platform that enables significant advances in the drug development process,” said Tom Grundstrom, Quintiles Infosario Global Head. “The innovative technology makes it possible to turn the wealth of data that our company possesses into actionable insights for our customers. Through the platform’s intuitive user interface, key stakeholders will be able to make faster, better-informed decisions about the programs and therapies they are working on.”
Addressing the challenges of the biopharmaceutical industry’s ever-changing landscape, Quintiles’ latest reporting and analytics technology integrates, synchronizes and standardizes subject, operational and management data automatically across a multitude of systems. The platform transforms data and information into meaningful insights to Quintiles’ customers using a secure, web-based front end with a simple, easy to navigate drill path from insight to clinical data. Quintiles Infosario’s reporting and analytics capabilities are among the first features that will be available to select customers beginning later this month.
In addition, customers can fulfill all or parts of their clinical IT system needs through Quintiles Infosario’s cloud-based Systems as a Service. Infosario combines IT provisioning, including configured systems with core clinical business process delivery. By using Systems as a Service, customers will have direct, cost-effective access to state-of-the-art IT systems such as safety management and clinical trial management – the same systems that serve Quintiles business.
“The release of Quintiles Infosario marks an important new day for both the biopharmaceutical industry and those patients who benefit from their breakthroughs,” said Paula Brown Stafford, President of Quintiles Clinical Development. “At Quintiles, we believe our broad expertise uniquely positions us to partner with leading biopharmaceutical companies to turn foundational data into transformational information that can be used to greatly improve patient outcomes.”
For more information, visit: www.Quintiles.com/infosario
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of 20,000 engaged professionals in more than 60 countries around the globe works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.